Tech Company Financing Transactions
Metabolex Funding Round
Metabolex, based in Newark, scored $27 million in investment from Bay City Capital, CLS and KBC Securities.
Transaction Overview
Company Name
Announced On
8/26/2003
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Undisclosed
Investors
Proceeds Purpose
In particular, it will allow us to complete Phase II studies of our novel insulin sensitizer, metaglidasen, as well as advance the development of additional compounds from our portfolio of potential drug candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7999 Gateway Blvd. 130
Newark, CA 94560
USA
Newark, CA 94560
USA
Phone
Website
Email Address
Overview
Metabolex, Inc. is a privately held pharmaceutical company dedicated to the discovery and development of drugs to treat diabetes and related metabolic disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Harold Wart
Chief Financial Officer
Sujal Shah
Chief Medical Officer
Pol Boudes
VP - Bus. Development
Patrick O'Mara
VP - R & D
Charles McWherter
Browse more venture capital transactions:
Prev: 8/25/2003: Zilliant venture capital transaction
Next: 8/26/2003: Secure Software venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs